CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞疗法与双特异性抗体在大 B 细胞淋巴瘤、滤泡性淋巴瘤和套细胞淋巴瘤早期治疗线中的应用
英文原题：Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
查看英文原题
Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
细胞疗法，包括CAR-T 细胞疗法和双特异性抗体（BsAbs），已经彻底改变了多种B细胞非霍奇金淋巴瘤的治疗。目前已有多种药物获得监管机构批准用于治疗大B细胞淋巴瘤、滤泡性淋巴瘤和套细胞淋巴瘤，还有更多药物正在审评中。值得注意的是，虽然目前的批准是针对复发/难治性 setting 中的单药治疗，但临床试验正在研究联合治疗方案，以及将细胞疗法和BsAbs纳入更早期治疗线。本文聚焦于用于治疗各种淋巴瘤的细胞疗法和BsAbs，包括回顾已完成或正在进行的、在更早期治疗线中使用这些平台的试验，这些试验有可能在不久的将来改变临床实践。
展开英文摘要原文
Cellular therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies (BsAbs), have revolutionized the treatment of various B-cell non-Hodgkin lymphomas. A number of agents are now approved by regulatory agencies for treatment of large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, and more agents are currently under review.
Notably, while the current approvals are for single agents in the relapsed/refractory setting, clinical trials are now investigating combination approaches as well as incorporating cellular therapies and BsAbs into earlier lines of treatment. This article focuses on cellular therapies and BsAbs for treatment of various lymphomas, including review of completed or ongoing trials of using these platforms in earlier lines which have the potential to be practice changing in the near future.
论文信息
- 作者
- Nizamuddin IA、Ghobadi A
- 单位
- Washington University in St Louis School of Medicine, Saint Louis, MO.United States
- 文献类型
- 综述
- 期刊
- American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2025 Jun
- 原文标识
- PubMed 40446182 · DOI 10.1200/EDBK-25-473302